GILD Gilead Sciences Inc

Gilead Sciences, Inc. (GILD) is currently at $73.54, up $3.84 or 5.51%

-- Would be highest close since Oct. 18, 2018, when it closed at $74.17

-- On pace for largest percent increase since Aug. 30, 2017, when it rose 7.25%

-- Gilead is testing an antiviral drug called remdesivir as a treatment for COVID-19. Trials are currently under way in China to test the drug, though The Wall Street Journal reported on Feb. 18 that the company has had trouble recruiting patients

-- Currently up three of the past four days

-- Currently up two consecutive days; up 9.76% over this period

-- Best two day stretch since the two days ending Aug. 31, 2017, when it rose 10.52%

-- Up 16.36% month-to-date; on pace for best month since Jan. 2018, when it rose 16.97%

-- Up 13.17% year-to-date

-- Down 39.82% from its all-time closing high of $122.21 on June 23, 2015

-- Would be a new 52-week closing high

-- Up 19.34% from its 52-week closing low of $61.62 on Oct. 2, 2019

-- Traded as high as $74.52; highest intraday level since Oct. 19, 2018, when it hit $74.80

-- Up 6.92% at today's intraday high; largest intraday percent increase since Feb. 3, 2020, when it rose as much as 8.67%

-- Best performer in the S&P 500 today

-- Best performer in the Nasdaq 100 today

All data as of 10:34:39 AM

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

February 24, 2020 10:56 ET (15:56 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.